When The Mighty Fall, Smaller Vaccine Players Seize The COVID Day

Agile Decisions Make The Difference

While global vaccine heavyweights such as Merck & Co, Sanofi and GSK have somewhat lagged in the development of vaccines for COVID-19, smaller players have stepped up. This is especially true for highly segmented markets such as China, where agility has been important.

Different types of Covid-19 coronavirus vaccines to protect against disease or pandemic
SMALLER PLAYES SEIZE THE DAY IN COVID VACCINES DEVELOPMENT • Source: Shutterstock

Globally, a number of smaller players have shone in the development of coronavirus vaccines and that has also been the case in China, where the market is highly fragmented and hundreds of makers are vying for a share of the lucrative sector.

More from COVID-19

Arcturus and CSL Take on Pfizer With Longer-Lasting COVID Vaccine

 
• By 

Kostaive is the first self-amplifying mRNA COVID-19 vaccine to receive approval from the European Commission and could provide serious competition to Pfizer/BioNTech's Comirnaty and Moderna's Spikevax.

Under-Pressure Moderna Banks $590m To Speed Up Bird Flu Vaccine

 
• By 

A week after a downbeat forecast at J.P. Morgan Healthcare Conference, the US mRNA specialist has pocketed another sizeable sum from the US Department of Health and Human Services to accelerate development of an H5N1 mRNA pandemic influenza vaccine.

Stock Watch: Q3, Bonfire Of The Vaccine Manufacturers

 
• By 

Pfizer’s and Moderna’s quarterly pandemic-related product sales could not mask other weaknesses while GSK’s quarter was marred by unimpressive non-pandemic vaccines sales.

Meiji Considers Legal Action Amid Japan Misinformation On Kostaive Vaccine

 
• By 

Japanese distributor Meiji Seika Pharma is considering possible legal action against what it views as online slander around COVID-19 vaccine Kostaive, which received its global-first approval in Japan last year and has now been launched for regular vaccination in the country.

More from Scrip

Orphans Cling On To Growth Advantage As Market Share Heads Towards 20%

 

It might be the beginning of the end for the orphan drugs party but there is still sales growth enjoyment to be had for the sector, whose star performers are now looking increasingly like mainstream drugs.

Boehringer Boss Talks Tariffs And State Of Play In The US

 
• By 

The German firm’s chairman, Hubertus von Baumbach, is adopting a ‘wait-and-see’ approach to the threat of pharma tariffs.

Trump Tariffs – Indian Pharma Dodges Bullet, But Sword Still Hangs?

 
• By 

Trump announced a 26% reciprocal tariff on India but a country-agnostic exemption of pharmaceuticals implies that the interests of Indian firms and the US consumer are protected for now. What is Indian pharma’s business exposure and what is domestic industry saying?